The analyses showed that the use of oral contraceptives in BRCA1/2-pV carriers initially led to an increased risk of breast cancer and in the long term to a reduced risk of ovarian and endometrial cancer (Schrijver et al. 2022). The gene discussed is BRCA1; the disease is endometrial cancer.